Back

Choosing the most effective and safest P2Y12 Inhibitor for use in >70-year-old acute coronary syndrome patients: a network meta-analysis

30 August 2024 (15:00 - 15:50)
Organised by: Logo
Congress Presentation Part of: Drug interactions, efficacy, and safety Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Mohamed Abouzid

Poznan University of Medical Sciences, Poznan (Poland)

7 More presentations in this session

Presentation thumbnail
Adverse cardiovascular outcomes due to potential drug-drug interactions in statin therapy: a population-based study
Ms A. Lai (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Modulation of p300 acetylation to protect against doxorubicin-induced cardiotoxicity
Mr J. Lee (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Development of a cardiotoxicity evaluation system using a Heart-on-a-Chip Microdevice with aligned fiber device
Doctor K. Murata (Kobe, JP)
Abstract Slides Video
Presentation thumbnail
Drug-drug interactions of empagliflozin and dapagliflozin
Professor C. Stoellberger (Wien, AT)
Abstract Slides Video
Presentation thumbnail
Pregnancy protection in women of child-bearing age prescribed ACE inhibitors, ARBs or statins - A nationwide cohort study
Mr S. Nielsen (Hellerup, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Drug interactions, efficacy, and safety

The Event

Event poster

ESC Congress 2024

30 August 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
One- and five-year mortality according to first use of ticagrelor or clopidogrel at the acute stage of myocardial infarction in elderly patients: the FAST-MI 2015 registry
thumbnail
Congress Presentation
Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis
thumbnail
Congress Presentation
Comparative discontinuation and non-bleeding side effects of Clopidogrel, Prasugrel and Ticagrelor in patients with acute coronary syndromes; a Network Meta-analysis of Randomized Controlled Trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources